Cargando…
Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates
Stimulator of interferon genes (STING) is a cytoplasmic dinucleotide sensor used as an immunomodulatory agent for cancer treatment. The efficacy of the STING ligand (STING-L) against various tumors has been evaluated in mouse models; however, its safety and efficacy in non-human primates have not be...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813482/ https://www.ncbi.nlm.nih.gov/pubmed/36620070 http://dx.doi.org/10.1016/j.omtm.2022.12.008 |
_version_ | 1784863930749812736 |
---|---|
author | Takahama, Shokichi Ishige, Kazuya Nogimori, Takuto Yasutomi, Yasuhiro Appay, Victor Yamamoto, Takuya |
author_facet | Takahama, Shokichi Ishige, Kazuya Nogimori, Takuto Yasutomi, Yasuhiro Appay, Victor Yamamoto, Takuya |
author_sort | Takahama, Shokichi |
collection | PubMed |
description | Stimulator of interferon genes (STING) is a cytoplasmic dinucleotide sensor used as an immunomodulatory agent for cancer treatment. The efficacy of the STING ligand (STING-L) against various tumors has been evaluated in mouse models; however, its safety and efficacy in non-human primates have not been reported. We examined the effects of escalating doses of cyclic-di-adenosine monophosphate (c-di-AMP) or cyclic [G (3′,5′)pA (3′,5′p] (3′-3′-cGAMP) administered intramuscularly or intravenously to cynomolgus macaques. Both ligands induced transient local and systemic inflammatory responses and systemic immunomodulatory responses, including the upregulation of interferon-α (IFN-α) and IFN-γ expression and the activation of multiple immunocompetent cell subsets. Better immunological responses were observed in animals that received c-di-AMP compared with those that received 3′-3′-cGAMP. Multi-parameter analysis using a dataset obtained before administering the ligands predicted the efficacy outcome partially. Importantly, the efficacy of these ligands was reduced in older macaques. We propose that 0.5 mg/kg c-di-AMP via intramuscular administration should be the optimal starting point for clinical studies. Our study is the first to demonstrate the age-dependent safety and efficacy of STING-L in non-human primates and supports the potential of STING-L use as a direct immunomodulator in vivo. |
format | Online Article Text |
id | pubmed-9813482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-98134822023-01-05 Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates Takahama, Shokichi Ishige, Kazuya Nogimori, Takuto Yasutomi, Yasuhiro Appay, Victor Yamamoto, Takuya Mol Ther Methods Clin Dev Original Article Stimulator of interferon genes (STING) is a cytoplasmic dinucleotide sensor used as an immunomodulatory agent for cancer treatment. The efficacy of the STING ligand (STING-L) against various tumors has been evaluated in mouse models; however, its safety and efficacy in non-human primates have not been reported. We examined the effects of escalating doses of cyclic-di-adenosine monophosphate (c-di-AMP) or cyclic [G (3′,5′)pA (3′,5′p] (3′-3′-cGAMP) administered intramuscularly or intravenously to cynomolgus macaques. Both ligands induced transient local and systemic inflammatory responses and systemic immunomodulatory responses, including the upregulation of interferon-α (IFN-α) and IFN-γ expression and the activation of multiple immunocompetent cell subsets. Better immunological responses were observed in animals that received c-di-AMP compared with those that received 3′-3′-cGAMP. Multi-parameter analysis using a dataset obtained before administering the ligands predicted the efficacy outcome partially. Importantly, the efficacy of these ligands was reduced in older macaques. We propose that 0.5 mg/kg c-di-AMP via intramuscular administration should be the optimal starting point for clinical studies. Our study is the first to demonstrate the age-dependent safety and efficacy of STING-L in non-human primates and supports the potential of STING-L use as a direct immunomodulator in vivo. American Society of Gene & Cell Therapy 2022-12-14 /pmc/articles/PMC9813482/ /pubmed/36620070 http://dx.doi.org/10.1016/j.omtm.2022.12.008 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Takahama, Shokichi Ishige, Kazuya Nogimori, Takuto Yasutomi, Yasuhiro Appay, Victor Yamamoto, Takuya Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates |
title | Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates |
title_full | Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates |
title_fullStr | Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates |
title_full_unstemmed | Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates |
title_short | Model for predicting age-dependent safety and immunomodulatory effects of STING ligands in non-human primates |
title_sort | model for predicting age-dependent safety and immunomodulatory effects of sting ligands in non-human primates |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813482/ https://www.ncbi.nlm.nih.gov/pubmed/36620070 http://dx.doi.org/10.1016/j.omtm.2022.12.008 |
work_keys_str_mv | AT takahamashokichi modelforpredictingagedependentsafetyandimmunomodulatoryeffectsofstingligandsinnonhumanprimates AT ishigekazuya modelforpredictingagedependentsafetyandimmunomodulatoryeffectsofstingligandsinnonhumanprimates AT nogimoritakuto modelforpredictingagedependentsafetyandimmunomodulatoryeffectsofstingligandsinnonhumanprimates AT yasutomiyasuhiro modelforpredictingagedependentsafetyandimmunomodulatoryeffectsofstingligandsinnonhumanprimates AT appayvictor modelforpredictingagedependentsafetyandimmunomodulatoryeffectsofstingligandsinnonhumanprimates AT yamamototakuya modelforpredictingagedependentsafetyandimmunomodulatoryeffectsofstingligandsinnonhumanprimates |